ReviewJournal of endocrinological investigation2017
Pegvisomant in acromegaly: an update.
Review in Journal of endocrinological investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies.Endocrine · 2019Pooled it
- Acromegaly and Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical and Therapeutic Implications.Current obesity reports · 2026Review
- Acromegaly complications: an update.The Journal of clinical endocrinology and metabolism · 2026Review
- Consensus on acromegaly complications: an update.Pituitary · 2026Article
- Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort.Pituitary · 2026Article
- To test or not to test: what we have learnt from 50 years of dynamic testing in acromegaly.Pituitary · 2026Review
- Acromegaly treatment and bone: a bidirectional relationship.Pituitary · 2025Review
- Consensus on acromegaly therapeutic outcomes: an update.Nature reviews. Endocrinology · 2025Review
- The feedback loop in pituitary surgery.Pituitary · 2025Article
- Artificial intelligence in acromegaly: Why, when and how.Pituitary · 2025Article
- Is Knosp enough? A novel classification for Acromegaly: a retrospective analysis of cure rates and outcome predictors in a large tertiary centre.Acta neurochirurgica · 2025Article
- IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly.Pituitary · 2024Article
- Insights from an Italian Delphi panel: exploring resistance to first-generation somatostatin receptor ligands and guiding second-line medical therapies in acromegaly management.Journal of endocrinological investigation · 2024Article
- [Cephalgic syndrome in patients with acromegaly].Problemy endokrinologii · 2024Review
- GIGANTISM AND ACROMEGALY THROUGH HISTORY.Acta clinica Croatica · 2024Review
- Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE).Pituitary · 2024Article
- Review
- Pituitary gigantism due to a novelEndocrine oncology (Bristol, England) · 2024Article
- Acromegaly and Bone: An Update.Endocrinology and metabolism (Seoul, Korea) · 2023Review
- Analysis of Nephrolithiasis Treatment in Highest Reference Hospital-Occurrence of Acromegaly in the Study Group.Journal of clinical medicine · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since then, new evidence emerged on the biochemical and clinical effects of PEG and on its long-term efficacy and safety.
aimWe here reviewed the emerging aspects of the use of PEG in clinical practice in the light of the most recent literature.
resultsThe clinical use of PEG is still suboptimal, considering that it remains the most powerful tool to control IGF-I in acromegaly allowing to obtain, with a pharmacological treatment, the most important clinical effects in terms of signs and symptoms, quality of life and comorbidities. The number of patients with acromegaly exposed to PEG worldwide has become quite elevated and the prolonged follow-up allows now to deal quite satisfactorily with many clinical issues including major safety issues, such as the concerns about possible tumour (re)growth under PEG. The positive or neutral impact of PEG on glucose metabolism has been highlighted, and the clinical experience, although limited, with sleep apnoea and pregnancy has been reviewed. Finally, the current concept of somatostatin receptor ligands (SRL) resistance has been addressed, in order to better define the acromegaly patients to whom the PEG option may be offered.
conclusionsPEG increasingly appears to be an effective and safe medical option for many patients not controlled by SRL but its use still needs to be optimized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.